Biocon Ltd. Share Price

biocon wait for the dip opportunity to invest

Biocon:Malaysia Unit Gets MHRA Approval for Insulin Facility

NIFTY TECHNICAL LEVEL & DERIVATIVE ANALYSIS

NIFTY BULLISH BREAKOUT ZONE 23350 NIFTY BEARISH BREAKOUT ZONE 23200 OPEN INTEREST UPDATES IN OPTION CHAIN : HIGHER OPEN INTEREST SEEN @ 23500 CALL & 23000 PUT. AS PER DATA ANALYSIS MARKET STILL LOOKS RANGEBOUND. AS PER OPTION CHAIN ANALYSIS 23500, 23700 LOOKS STRONG RESISTANCE LEVEL. IN LAST 3 DAYS NIFTY TRY TO BREAK 23500 LEVEL BUT NOT SUCCESS BECAUSE HEAVY CALL SELLING SEEN @ 23500 LEVEL AND 23000 WILL PLAY AS A KEY SUPPORT LEVEL IN LAST 3 DAYS MAXIMUM PUT WRITING SEEN @ 23000 LEVEL. TODAY MORNING MARKET WILL OPEN GAP DOWN BUT THIS GAP DOWN WILL GIVE BUY OPPORTUNITY TO INTRADAY PLAYER. INTRDAY PLAYER BUY WITH 23400 LEVEL TARGET. AND IF NIFTY BREAK 23200 LEVEL THAN SHORT SIDE OPPORTUNITY WILL ARISE. FII LONG SHORT RATIO IS 10.69% INDICATES MARKET IS TRADING IN OVERSOLD ZONE.

Stock on radar for the day - Biocon spurts 3%

Biocon spurts 3% as Pertuzumab drug moves closer to marketing nod in Europe

Biocon’s Pertuzumab Becomes First Biosimilar

Biocon Brazil Expansion: 10-Year Biosimilar Deal

Biocon Limited has secured an exclusive 10-year supply contract for Pertuzumab—a biosimilar monoclonal antibody used to treat HER2-positive breast cancer—in Brazil through a consortium with public pharmaceutical laboratory Bahiafarma and biotechnology firm Bionovis. Under Brazil’s Productive Development Partnership (PDP) program, the consortium received a 100% market allocation, granting exclusive access to the country's public healthcare system (Unified Health System or SUS), which commands roughly 70% of Brazil's total demand for the oncology treatment. Throughout the decade-long agreement, Biocon will earn milestone payments and receive a defined share of revenues generated through the public procurement framework. The partnership marks a strategic expansion of Biocon’s commercial footprint in Latin America while addressing a critical, high-cost pharmaceutical need for Brazil, where Pertuzumab is not currently produced locally. Over the medium to long term, the PDP agreement mandates a phased technology transfer to establish local biopharmaceutical manufacturing capabilities within Brazil. By combining Biocon’s biomanufacturing and development expertise with Bahiafarma’s public health reach and Bionovis’ specialized biological capabilities, the collaboration expands global access to complex cancer therapies while advancing Brazil’s domestic production self-reliance.